ClinicalTrials.gg

Program

Tamoxifen

Also written as “tamoxifen”, “Tamoxifen (Nolvadex)” and “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”.

Its studies are mostly in Breast Neoplasms · Neoplasms · Ovarian Neoplasms, led by 6 companies.

Furthest: phase 4, since Sep 30, 200514 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca80 open or runningphase 3since Sep 30, 2005Sep 30, 2005none ahead
Pfizer20 open or runningphase 4since Aug 25, 2010May 8, 2002none ahead
Changchun GeneScience Pharmaceutical11 open or runningphase 3since May 31, 2024May 31, 2024none ahead
Daré Bioscience10 open or runningphase 2since May 2, 2022May 2, 2022none ahead
Mediclinic Middle East10 open or runningphase 2since Mar 14, 2019Mar 14, 2019none ahead
Nalagenetics Pte10 open or runningno phasesince Aug 12, 2022Aug 12, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2002First study: phase 3 study in Breast NeoplasmsNew to PfizerPfizer · NCT00036270 · 9,779 enrolled · United States
  2. Sep 30, 2005AstraZeneca's first study: phase 3 study in Breast NeoplasmsNew to AstraZenecaAstraZeneca · NCT00232661 · 452 enrolled · United States, Belgium, Brazil and more
  3. Feb 13, 2006Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00291759 · 3,858 enrolled · Austria
  4. Nov 3, 20084 phase 3 studiesAstraZeneca · NCT00814125, NCT00784940, NCT00784862 and 1 more
  5. Feb 20, 2009Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00849030 · 9,358 enrolled
  6. Aug 25, 2010Phase 4 study in PharmacokineticsPfizer · NCT01189500 · 30 enrolled · United States
  7. Mar 6, 2014Phase 1 study in NeoplasmsAstraZeneca · NCT02093351 · 79 enrolled · Belgium, Denmark, France and more
  8. Mar 14, 2019Mediclinic Middle East's first study: phase 2 study in Breast Cancer FemaleNew to Mediclinic Middle EastMediclinic Middle East · NCT03879174 · 25 enrolled · United Arab Emirates
  9. May 2, 2022Daré Bioscience's first study: phase 2 study in Vulvar AtrophyNew to Daré BioscienceDaré Bioscience · NCT05378269 · 17 enrolled · Australia
  10. Aug 12, 2022Nalagenetics Pte's first study: no phase study in Breast NeoplasmsNew to Nalagenetics PteNalagenetics Pte · NCT05501158 · 150 enrolled · Indonesia
  11. May 31, 2024Changchun GeneScience Pharmaceutical's first study: phase 3 study in Breast Cancer SubjectsNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT06449027 · 211 enrolled · China

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha modulator”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06449027Breast Cancer Subjects · China3Active, not recruitingChangchun GeneScience PharmaceuticalNov 2025211
NCT05501158Breast Neoplasms · Indonesia–UNKNOWNNalagenetics PteApr 30, 2024150
NCT05378269Vulvar Atrophy · Australia2CompletedDaré BioscienceDec 20, 202217
NCT03879174Breast Cancer Female · United Arab Emirates2UNKNOWNMediclinic Middle EastAug 1, 202225
NCT02093351Neoplasms · Belgium, Denmark, France and more1CompletedAstraZenecaApr 30, 201579
NCT01189500Pharmacokinetics · United States4CompletedPfizerOct 201030
NCT00849030Breast Neoplasms3CompletedAstraZenecaJun 20019,358
NCT00814125Breast Neoplasms3CompletedAstraZeneca285
NCT00784940Bone Density3CompletedAstraZenecaMar 2005308
NCT00784862Breast Neoplasms3CompletedAstraZeneca9,358
NCT00784680Quality of Life3CompletedAstraZeneca308
NCT00291759Breast Neoplasms · Austria3CompletedAstraZenecaJun 20093,858
NCT00232661Breast Neoplasms · United States, Belgium, Brazil and more3CompletedAstraZenecaJan 2003452
NCT00036270Breast Neoplasms · United States3CompletedPfizerOct 20089,779

How it is read

Names in the registry

  • “Tamoxifen”, 11 entries
  • “tamoxifen”, 2 entries
  • “Tamoxifen (Nolvadex)”, 2 entries
  • “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”, 1 entry
  • “T Leuprolide Injectable Emulsion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.